Medicare Drug Price Negotiation: Close the Pharmacy Refund Gap

A paid pharmacy claim is no longer necessarily a finished transaction. For drugs subject to Medicare’s negotiated prices, the dispensing entity may also need a manufacturer refund to obtain access to the applicable maximum fair price. That creates a second financial track alongside the Part D claim—and a new place for cash to disappear between dispensing, data transmission, payment, and reconciliation.

The first negotiated prices under the Medicare Drug Price Negotiation Program took effect on January 1, 2026. By October, this is no longer a launch-readiness exercise. Physician-owned pharmacies, health-system specialty pharmacies, and practices with integrated dispensing operations should be asking whether their actual receipts match the transactions they expected. Practices without a dispensing operation still need to understand the distinction when patients encounter pharmacy access problems.

The year-end task is deceptively simple: identify which transactions belong in this workflow, determine how the dispensing entity receives access to the negotiated price, and prove that every refund or adjustment reached the right account. A familiar claim status—paid—cannot answer all three questions.

1. Start with the Part D boundary

The initial group of selected drugs has negotiated prices effective in 2026 under Medicare Part D. CMS calls those negotiated prices maximum fair prices, or MFPs. The first group includes drugs such as Eliquis, Jardiance, Entresto, and Stelara. Use CMS’s selected-drug and pricing files, including the applicable National Drug Codes, rather than building a permanent eligibility list from brand names.

This matters especially in multispecialty organizations. A product appearing in the negotiation program does not mean every administration, prescription, or purchase involving that product belongs in the same refund workflow. Confirm the benefit under which the transaction was covered, the particular product dispensed, and the applicable program requirements. Do not apply a Part D pharmacy reconciliation method automatically to a medical-benefit buy-and-bill claim.

The MFP is also not simply the amount the Part D plan must pay the pharmacy on its claim. Manufacturer obligations to provide access to the negotiated price and the pharmacy’s reimbursement arrangements with a plan or pharmacy benefit manager are related economically but are not interchangeable.

Build a scope table that connects each relevant product to the dispensing location, billing entity, benefit, acquisition channel, and refund arrangement. That small piece of groundwork prevents an expensive category error: chasing a manufacturer refund for the wrong transaction while overlooking eligible dispensing at another location.

2. Understand why a paid claim can remain financially open

A dispensing entity may obtain access to the MFP through an upfront arrangement or through a retrospective manufacturer refund. Under a retrospective approach, the pharmacy can purchase inventory, dispense the drug, receive payment on the Part D claim, and receive the manufacturer refund later. Those events do not necessarily occur in the same accounting period.

Consider a hypothetical specialty pharmacy that dispenses a selected drug near month-end. The claim adjudicates successfully, and the patient receives the prescription. The pharmacy records its acquisition expense and claim reimbursement. If the associated manufacturer refund arrives the following month, a report built only from pharmacy claims and wholesaler invoices can present an incomplete picture of that prescription’s economics.

The opposite problem is just as serious. Recording an expected refund without checking eligibility, quantities, and the manufacturer’s applicable process can overstate receivables. A spreadsheet formula that subtracts MFP from an invoice price is not, by itself, proof of what the manufacturer owes.

Keep three questions separate: Did the payer adjudicate the claim correctly? Did the dispensing entity receive the appropriate access to MFP? Did the combined transaction produce the expected margin after acquisition costs and applicable fees? One answer cannot substitute for the others. The refund is not a bonus payment, and a successful refund does not establish that the underlying payer reimbursement was correct.

3. Test the Medicare Transaction Facilitator connection

CMS established the Medicare Transaction Facilitator, or MTF, to support the exchange of information needed for MFP access and, through its payment functionality, to facilitate manufacturer refund payments. The data workflow relies on Part D prescription drug event information. It is not merely another view of the pharmacy’s point-of-sale claim response.

That distinction explains why a prescription can look complete in the dispensing system while the associated manufacturer transaction has not yet reached the same stage. Claim adjudication, plan reporting, data processing, and refund handling are separate events. Staff need visibility into those handoffs rather than a single status imported from the pharmacy system.

Verify the operational connection for every dispensing entity and location involved. Enrollment completed by a corporate office does not guarantee that a recently acquired pharmacy, changed bank account, or new location has been mapped correctly. Also establish whether each manufacturer uses the MTF payment functionality or an alternative payment process; do not assume every refund will arrive through the same channel.

• Confirm that identifying information matches across pharmacy records, program enrollment, and payment instructions.
• Validate bank details and remittance access through established security procedures.
• Identify who can retrieve transaction records and who can resolve access problems.
• Document each manufacturer’s refund route and support or dispute process.
• Trace a completed transaction from dispensing record to refund detail and bank deposit before declaring the connection operational.

4. Build a ledger that connects the claim to the cash

The reconciliation unit should be the dispensing transaction, not the manufacturer’s total monthly deposit. A deposit can combine multiple prescriptions, locations, and adjustments. Matching the deposit to a general-ledger account proves that money arrived; it does not prove that every eligible prescription was included or paid correctly.

Create a crosswalk between the pharmacy claim, relevant MTF transaction information, manufacturer remittance, and cash receipt. Preserve original identifiers when transactions are corrected. Otherwise, a rebill can look like a new receivable while the original remains open, creating both a false shortage and a false asset.

Store expected amounts with their calculation basis and source. Where the manufacturer’s applicable methodology uses a standard refund calculation, distinguish that calculation from the pharmacy’s actual acquisition economics. A refund computed correctly under the relevant methodology does not necessarily resolve every acquisition-cost concern; discrepancies may require a separate inquiry.

Avoid dropping detailed patient or prescription information into broadly shared accounting workbooks. Use role-based access, secure transfers, and the minimum information necessary for the reconciliation task. Finance needs a reliable transaction match, not unrestricted access to the clinical chart.

• Dispensing entity and location identifiers; prescription reference and fill number.
• Date of service, product NDC, quantity, and unit convention.
• Payer claim status and links to reversals or replacement claims.
• Applicable MFP information, expected refund basis, and manufacturer.
• Data-transmission status, refund reference, payment date, and matched deposit.
• Exception reason, responsible owner, next action, and resolution evidence.

5. Age each handoff—not just the date of dispensing

CMS’s program guidance generally requires manufacturers using a retrospective refund approach to provide access to MFP within 14 days after receiving the relevant claim-level data from the MTF. That is not the same as promising cash within 14 days after the prescription leaves the pharmacy. The difference belongs in every cash forecast and escalation policy.

An aging report based only on the dispensing date mixes together fundamentally different problems. One transaction may still be waiting for the necessary data to reach the manufacturer. Another may have reached the manufacturer but lack a corresponding payment. A third may already be paid but remain unmatched because the remittance landed in an unattended portal.

Create separate queues for missing downstream data, manufacturer-stage transactions, payment discrepancies, and unmatched cash. Where a timestamp is unavailable, label it unavailable rather than estimating it and presenting the estimate as fact. Staff should know which party can actually investigate each gap.

Track total elapsed time from dispensing to receipt as an internal cash-flow measure. Track the manufacturer-stage timing separately when the relevant receipt information is available. This gives management a useful answer to two different questions: How long are we financing the transaction, and which handoff needs intervention? A single average days-to-payment figure can conceal both a reporting bottleneck and a reconciliation backlog.

6. Treat reversals and rebills as refund events

Pharmacy operations generate changes after initial adjudication: prescriptions are returned to stock, quantities are corrected, coverage is updated, or a claim is reversed and rebilled. Those changes can affect the underlying basis for an MFP refund. The revenue cycle cannot close the manufacturer side permanently while the pharmacy side is still changing.

Use a daily or otherwise appropriately frequent adjustment feed to identify selected-drug transactions with reversals, replacement claims, or quantity changes. Link each event to the original dispensing record and any associated refund. Then follow the applicable process for resolving payment changes rather than assuming that every correction will reconcile itself automatically.

For example, a prescription that was paid and later returned to stock should not remain in the ledger as an ordinary completed dispensing with an unquestioned refund entitlement. Conversely, a corrected rebill should not disappear from refund monitoring merely because the original claim was reversed.

Require evidence before closing an adjustment. That evidence might include a replacement transaction, manufacturer adjustment detail, or a documented resolution through the relevant support channel. Keep unresolved differences visible to accounting at month-end. The practical control is a two-way check: every material pharmacy adjustment should prompt a refund review, and every manufacturer adjustment should trace back to an identifiable transaction or documented explanation.

7. Give 340B transactions a separate review path

Organizations participating in the 340B Drug Pricing Program need an additional control. The negotiation program contains provisions addressing the interaction between MFP and 340B pricing; it is not designed to provide an unrestricted second discount on top of 340B pricing. Applicable treatment depends on the relationship between the prices and the transaction’s circumstances.

Do not label an entire pharmacy’s dispensing as 340B or non-340B based solely on the organization’s participation. The relevant status must be determined through the organization’s actual 340B process. Contract-pharmacy arrangements, replenishment workflows, and later status changes make shortcuts particularly risky.

Bring the 340B administrator, pharmacy finance lead, and compliance team into the same reconciliation process. They should agree on how transaction status is established, when that status becomes available, and how corrections reach the team handling MFP refunds. Use current CMS guidance and the applicable manufacturer process for disputes or requests for supporting information.

An unexplained reduction or missing refund should not immediately be treated as a routine payer denial. It may involve 340B treatment, data identification, or manufacturer reconciliation rather than claim adjudication. Preserve the evidence and route the issue accordingly. A generic denial work queue is a poor substitute for staff who understand both programs.

8. Assign ownership across pharmacy, billing, and finance

MFP reconciliation falls between departments unless someone explicitly owns it. Pharmacy controls dispensing and reversals. Contracting understands reimbursement terms. Finance sees deposits and receivables. Compliance handles sensitive program questions. None necessarily has the complete transaction history.

Name one operational owner with authority to coordinate those teams. Set a recurring exception meeting focused on unresolved transactions, not a presentation of total dollars received. Each item should leave the meeting with a responsible person, an evidence request, and a follow-up date. Keep payer claim disputes separate from manufacturer refund disputes even when both concern the same prescription.

If the organization uses outside medical billing services, verify whether the engagement actually covers pharmacy refund reconciliation. A contract covering professional claims, payment posting, and denial follow-up may not include MTF access, manufacturer remittances, or pharmacy-system adjustments. Access rights and responsibilities should be written down before the first unresolved balance is handed off.

The same discipline applies when integrated practices expand broader revenue cycle management services. Ask who owns missing transaction data, who matches manufacturer cash, and who approves accounting adjustments. Outsourcing a task should not outsource institutional knowledge of the refund methodology.

Use a compact dashboard: eligible transaction volume, unresolved expected refunds, unmatched receipts, adjustment backlog, and age by workflow stage. These are operating measures, not proof that every unresolved dollar is legally payable. Keep that distinction visible.

9. Close 2026 before the next price cycle complicates the ledger

The next group of negotiated prices takes effect on January 1, 2027. That makes the final months of 2026 a practical deadline for repairing weak reconciliation processes. More products and another effective-date boundary will make a brand-name spreadsheet or manually maintained deposit list harder to trust.

Version the product and pricing reference data. Retain the historical information needed to evaluate earlier dispensing transactions rather than overwriting it with the latest file. A refund received in January may relate to a prior-period prescription; the bank deposit date alone does not determine which pricing information belongs in the reconciliation.

Before year-end, perform a targeted closeout review across completed transactions, open refunds, reversals, and unmatched payments. Sample both clean-looking records and exceptions. A process that resolves only the loudest complaints can miss a systematic mapping error affecting otherwise ordinary transactions.

Review receivable treatment with accounting. Expected refunds, disputed amounts, and unidentifiable deposits should not all receive the same treatment simply because they sit in one spreadsheet. Document the support for material balances and the reasons unresolved items remain open.

• Refresh selected-product and effective-date reference data using current CMS materials.
• Test location identifiers, payment routes, and authorized portal access.
• Reconcile a sample from dispensing through manufacturer payment and bank posting.
• Resolve or document older exceptions before carrying balances into the new year.
• Confirm that pharmacy adjustments continue to trigger refund review after month-end close.